Project descriptionGlioblastoma Multiforme is an aggressive brain cancer with poor prognosis and survival. Resistance to chemotherapy often leads to recurrence of tumours. Pharmacological agents targeting cell motility are lacking. This project aims to characterise novel agents in primary cell lines derived from patient biopsy samples and is a part of the project funded by Neurosurgical Research Foundation Grant (2022-2023). The outcomes of this project will include information on cell viability and effective dose (IC50) response. This information will provide a platform for future translational studies.
Assumed knowledgeCell culture, Sterile techniques, Molecular biology, Human Physiology.
Note: You need to register interest in projects from different supervisors (not a number of projects with the one supervisor).
You must also contact each supervisor directly to discuss both the project details and your suitability to undertake the project.